Cours Viracta Therapeutics, Inc. Nasdaq
Actions
US92765F1084
Recherche biotechnologique et médicale
CA 2024 * | - | CA 2025 * | 2,33 M 2,11 M | Capitalisation | 32,99 M 29,79 M |
---|---|---|---|---|---|
Résultat net 2024 * | -62 M -55,98 M | Résultat net 2025 * | -83 M -74,95 M | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 14,1 x |
PER 2024 * |
-0,73
x | PER 2025 * |
-0,78
x | Employés | 40 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 97,2% |
Dernier transcript sur Viracta Therapeutics, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 19/09/22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 07/08/23 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01/10/07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01/02/21 |
Barry Simon
BRD | Director/Board Member | 59 | 03/03/21 |
Varia. 1 janv. | Capi. | |
---|---|---|
+29,77% | 49,46 Md | |
+1,00% | 42,58 Md | |
+49,79% | 42,49 Md | |
-5,26% | 29,09 Md | |
+13,68% | 26,61 Md | |
-22,99% | 18,64 Md | |
+8,22% | 13,16 Md | |
+32,41% | 12,55 Md | |
+24,01% | 12,1 Md |